Open AccessCarisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma
Author(s) -
Gunchan Paul,
Gautam Lal Parshotam,
Rajneesh Garg
Publication year - 2016
Publication title -
journal of anaesthesiology-clinical pharmacology/journal of anaesthesiology clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.466
H-Index - 32
eISSN - 2231-2730
pISSN - 0970-9185
DOI - 10.4103/0970-9185.173346
Subject(s) - neuroleptic malignant syndrome , medicine , dantrolene , anesthesia , muscle relaxant , antipsychotic , psychiatry , schizophrenia (object oriented programming) , calcium
Soma (Carisoprodol) is N-isopropyl-2 methyl-2-propyl-1,3-propanediol dicarbamate; a commonly prescribed, centrally acting skeletal muscle relaxant. Neuroleptic malignant syndrome (NMS) is a potentially life-threatening adverse effect of antipsychotic agents. Although diagnostic criteria for NMS have been established, it should be recognized that atypical presentations occur and more flexible diagnostic criteria than currently mandated, may be warranted. We wish to report a postoperative case of bilateral knee replacement who presented with carisoprodol (Soma) withdrawal resembling NMS that was a diagnostic dilemma. Subsequently, it was successfully treated with oral baclofen in absence of sodium dantrolene.